MONT-SAINT-HILAIRE, QUEBEC--(MARKET WIRE)--Jun 14, 2007 -- Axcan Pharma Inc. ("Axcan" or the "Company") (NasdaqGS:AXCA - News)(Toronto:AXP.TO - News) today announced the initiation of MAX-002, a Phase III clinical trial to evaluate the efficacy and safety of a novel, high-concentration, 1 gram mesalamine suppository for the treatment of ulcerative proctitis. The Company has also filed a formulation and process patent application for the drug, which, if granted, could provide protection until 2027. If approved, the Company would market this new product as part of its CANASA product line in the United States.
